Hepatitis B virus (HBV)-encoded X antigen (HBxAg) contributes to the development of hepatocellular carcinoma (HCC). A frequent characteristic of HCC is reduced or absent expression of the cell adhesion protein, Ecadherin, although it is not known whether HBxAg plays a role. To address this, the levels of E-cadherin were determined in HBxAg-positive and -negative HepG2 cells in culture, and in tumor and surrounding nontumor liver from a panel of HBV carriers. The results showed an inverse relationship between HBxAg and E-cadherin expression both in tissue culture and in vivo. In HBxAgpositive cells, E-cadherin was suppressed at both the mRNA and protein levels. This was associated with hypermethylation of the E-cadherin promoter. Depressed E-cadherin correlated with HBxAg trans-activation function, as did the migration of HepG2 cells in vitro. Decreased expression of E-cadherin was also associated with the accumulation of b-catenin in the cytoplasm and/ or nuclei in tissues and cell lines, which is characteristic of activated b-catenin. Additional work showed that HBxAg-activated b-catenin. Together, these results suggest that the HBxAg is associated with decreased expression of E-cadherin, accumulation of b-catenin in the cytoplasm and nucleus, and increased cell migration, which may contribute importantly to hepatocarcinogenesis.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is commonly associated with chronic hepatitis B virus (HBV) and hepatitis C virus infections. The finding that HBV makes a genetic contribution to HCC by expression of the HBV-encoded X antigen (HBxAg) (Henkler and Koshy, 1996; Feitelson and Duan, 1997) , suggests that the pathways whereby HBxAg contributes to hepatocarcinogenesis are relevant for the development of diagnostic/prognostic markers and/or antiviral and antitumor drugs.
HBxAg is a trans-activating protein that may promote tumor formation by altering the patterns of host gene expression (Caselmann, 1995) . HBxAg may do this by activating signal transduction pathways and by binding to transcription factors that influence host gene expression (Henkler and Koshy, 1996; Feitelson and Duan, 1997) . Among these changes, HBxAg upregulates the expression of cellular proteins that promote cell growth and survival (Su et al., 1994; Terradillos et al., 1997) , and suppresses expression or functionally inactivates negative growth regulatory proteins (Wang et al., 1994; Truant et al., 1995; Sun et al., 1998; Feitelson et al., 1999; Lian et al., 1999; Kondoh et al., 2001) . Although HBxAg is expressed in the liver throughout chronic infection (Wang et al., 1991) , it is not clear whether HBxAg downregulates the expression of some of these pathways by epigenetic mechanisms, such as DNA methylation (Kanai et al., 1997 (Kanai et al., , 2000 .
E-cadherin is a key cell adhesion protein that may also act as a tumor suppressor, since it inhibits cellular growth, transformation, and invasiveness (Christofori and Semb, 1999) . In HBV-associated HCC, reduced expression of E-cadherin is associated with loss of heterozygosity (LOH) at the E-cadherin locus (Slagle et al., 1993) . This was observed in large, metastatic HCC (Kanai et al., 2000; Matsumura et al., 2001) , and was associated with poor survival (Endo et al., 2000; Inayoshi et al., 2003) . In contrast, methylation of the E-cadherin promoter has been reported in preneoplastic liver and early tumors (Lee et al., 2003; Yang et al., 2003) , suggesting that the mechanism of reduced E-caherin expression differs at different times during the pathogenesis of HCC. Among c-myc transgenic mice that developed HCC, more than 70% showed reduced E-cadherin, and in some cases, this was associated with hypermethylation of the E-cadherin promoter (Calvisi et al., 2004) . Restoration of E-cadherin expression in HepG2 cells resulted in reduced cell growth in culture, and reduced clonability in soft agar (Masuda et al., 2000; Yano et al., 2001) , suggesting that E-cadherin also acts as a negative growth regulatory protein in HCC.
A major E-cadherin-binding protein, b-catenin, plays a critical role in Wnt signaling and in tumorigenesis (Wei et al., 2002) . E-cadherin-binding sequesters b-catenin to the cell membrane, where b-catenin signaling is inhibited (Gottardi et al., 2001) . Decreased E-cadherin expression in liver and tumor is associated with the cytoplasmic/nuclear redistribution of b-catenin (Endo et al., 2000; Prange et al., 2003) , with decreased cell adhesion, increased cell growth and motility, and with poor prognosis. The ability of E-cadherin to suppress tumor invasion depends upon its binding to b-catenin (Wong and Gumbiner, 2003) . The finding that roughly 20% of HCCs express a constitutively active mutant b-catenin , suggests that persistently elevated b-catenin is important in the pathogenesis of HCC. This is supported by the observation that E-cadherin suppresses cellular transformation by inhibiting b-catenin signaling (Gottardi et al., 2001) . The recent finding that Wnt/b-catenin signaling is activated in Wnt-1-treated HBxAg-positive cells (Cha et al., 2004) , suggests that HBxAg may promote elevated b-catenin signaling, in part, by downregulation of E-cadherin. The experiments outlined in this work were designed to test this hypothesis.
Results

Microarray and Powerblot analysis of HepG2X and HepG2CAT cells
Whole cell RNAs prepared from HepG2X and HepG2-CAT cells were subjected to microarray analysis. The results showed a decrease in E-cadherin (5.771.1-fold) and increase in b-catenin (4.970.8-fold) mRNAs in HepG2X compared to HepG2CAT cells (data not shown). To determine whether these differences were also detected at the protein level, whole cell lysates were analysed for differentially expressed proteins by Powerblot analysis. The results show that E-cadherin was 5.771.2-fold lower (Figure 1a and b) and b-catenin was 4.570.5-fold higher in HepG2X compared to HepG2-CAT cells (Figure 1c and d) . Hence, the introduction of HBxAg into HepG2 cells is associated with decreased levels of E-cadherin and increased levels of b-catenin.
Differential expression of E-cadherin in HepG2X compared to HepG2CAT cells
To confirm the results of microarray and Powerblot analyses, whole cell RNAs from HepG2X and HepG2-CAT cells were subjected to RT/PCR. The results of three experiments showed a 7.871.3-fold decrease in E-cadherin mRNA in HepG2X compared to HepG2CAT cells (Figure 2a) . Similar results were obtained by Western blotting, where E-cadherin levels were 7.271.7-fold lower in HepG2X cells grown in serumfree medium (Figure 2b , compare lanes 2 and 1), and 8.872.2-fold lower in HepG2X cells grown in medium containing 10% serum (Figure 2b , compare lanes 4 and 3). This suggests that HBxAg, and not growth factors in the medium, is associated with decreased levels of E-cadherin. Decreased membranous E-cadherin was also observed in HepG2X compared to HepG2CAT cells by immunostaining (Figure 2c and d) . Hence, HBxAg expression is inversely correlated with that of E-cadherin at both the mRNA and protein levels in tissue culture cells.
Expression of E-cadherin and HBxAg in HCC and nontumor liver To determine whether this inverse relationship also occurs in vivo, paired tumor (HCC) and nontumor (liver) samples from South African and Chinese HBV carriers with HCC were evaluated for HBxAg and E-cadherin expression. To determine E-cadherin expression levels, 22 randomly chosen HCCs were tested for E-cadherin by RT/PCR. Nine were positive, and eight of these nine were also positive by immunohistochemical staining, suggesting concordance at the RNA and protein levels. Consecutive sections of tissues were then stained for HBxAg. Among tumor samples from South African patients, eight of 12 (66%) were positive for HBxAg and three (25%) had detectable E-cadherin staining. However, no costaining was observed (w 2 ¼ 8; Po0.005). HBxAg was mostly cytoplasmic, with scattered nuclear staining in some cases, while E-cadherin staining was membranous (data not shown). In peritumor liver, HBxAg staining was observed in nine of 12 cases (75%), and E-cadherin staining was present in seven (58%). Costaining was observed in only three cases (25%) (w 2 ¼ 3.86; Po0.05). These results suggest an inverse relationship between HBxAg and E-cadherin exists in both tumor and nontumor tissues.
To determine whether this relationship exists in another population with a high incidence of HBVassociated HCC, parallel analysis was conducted on tumor/nontumor pairs from 184 Chinese patients. Costaining was observed in 35 tumors (19%) (w 2 ¼ 44.8; Po0.001) and in 74 nontumor livers (40%) (w 2 ¼ 14.6; Po0.001), although HBxAg and E-cadherin staining were in separate cells, suggesting an inverse correlation between their expression. This is exemplified in Figure 3 .
When the results from these populations were combined, and the total scores (TS) calculated from the intensity of staining and proportion of positive cells, the TS score for E-cadherin was 0.454570.8769 in HBxAg-positive HCC, while it was 1.390670.8659 (Po0.001) in HBxAg-negative HCC. The TS for Ecadherin for HBx-positive nontumor liver was 0.782670.7991, while for HBx-negative nontumor liver it was 1.810370.9264 (Po0.001). Hence, depressed E-cadherin expression is an early and persistent event in hepatocarcinogenesis in HBxAg-positive tissues.
When E-cadherin expression was compared to HCC stage, E-cadherin immunoreactivity was undetectable in six of 25 (24%) patients with grade I, in 34 of 110 (31%) with grade II, in 23 of 34 (68%) with grade III, and in 20 of 27 (74%) with grade IV HCC. This demonstrates an inverse relationship between E-cadherin expression and stage of HCC differentiation (w 2 ¼ 42.04, Po0.001).
Methylation status of the E-cadherin promoter in cell lines and clinical samples Given that methylation of the E-cadherin promoter occurs during hepatocarcinogenesis (Kanai et al., 1997; Lee et al., 2003; Yang et al., 2003) , and that HBxAg and E-cadherin expression is inversely related (Figures 1-3 ), experiments were designed to ask whether the downregulated expression of E-cadherin is associated with methylation of the E-cadherin promoter. When this work was performed, promoter methylation was 2.8-fold higher, and unmethylated promoter DNA was 5.1-fold lower, in HepG2X compared to HepG2CAT cells ( Figure 4a ). Hence, there was a roughly eightfold HBxAg downregulates E-cadherin in HCC J Liu et al shift in methylation of the E-cadherin promoter in HBxAgpositive cells compared to HBxAg-negative cells. When parallel analyses were carried out with clinical samples from 20 HBxAg-positive and 20 HBxAgnegative samples chosen at random from Chinese HCC patients, E-cadherin promoter methylation was detected in 16 HCC samples (80%) and 10 adjacent nontumor liver tissues (50%) from HBxAg-positive samples ( Figure 4b ). Among HBxAg-negative samples, E-cadherin promoter was mostly unmethylated in 12 HCC (60%) and in 18 adjacent nontumor samples (90%) (Figure 4c ). Further analysis showed a correlation between HBxAg expression and E-cadherin promoter methylation in both tumor and nontumor tissues (Po0.01). In HBxAg-positive HCC compared to HBxAg-negative HCC, the extent of methylation dropped about 6.770.7-fold, while in nontumor, the drop averaged 7.670.9-fold. Hence, E-cadherin promoter methylation appears to be an early event in hepatocarcinogenesis.
If the methylation of the E-cadherin promoter is triggered by HBxAg, then this should be observed in AML12-HBx cells, where HBxAg expression is under control of the tetracycline promoter. In uninduced cells, there is 8.471.7-fold more unmethylated compared to methylated promoter. When HBxAg is induced, there develops a 4.3570.56-fold increase in methylated E-cadherin promoter within 3 days of induction ( Figure 4d ) in three independent experiments. This further shows that HBxAg expression is associated with increased methylation of the E-cadherin promoter.
Relationship between HBxAg trans-activation, E-cadherin expression, and cell migration To see whether HBxAg promoted cell migration (LaraPezzi et al., 2001a, b) is linked to the suppression of E-cadherin in HCC (Nelson and Nusse, 2004) , several HBxAg mutants with different trans-activation levels were stably transfected into separate cultures of HepG2 cells (Figure 5a ), and each culture was assayed for E-cadherin mRNA and protein. When this was In (a) the densiometric values are compared to that of the unmethylated E-cadherin promoter. In the other panels, the ratio of unmethylated:methylated E-cadherin promoter DNA was calculated for each sample analysed and presented directly below each pair. HBxAg downregulates E-cadherin in HCC J Liu et al performed, the levels of E-cadherin mRNA in cells expressing wild-type HBxAg, or the HBxAg mutant lacking the carboxy-terminal 10 amino acids (HBx 1-135 ), were threefold lower that in pcDNA3-transfected cells (Figure 5b ). The levels of E-cadherin protein were fourto fivefold lower when the same comparisons were made (Figure 5c ). In contrast, E-cadherin mRNA and protein levels were near or above the levels observed in HepG2-pcDNA3 cells when these analyses were conducted on HepG2 cells transfected with HBxAg mutants with weak trans-activation activity (Figure 5b and c) . These observations suggest an inverse correlation between HBxAg trans-activation activity and the levels of Ecadherin. Given the importance of E-cadherin to cell adhesion (Nelson and Nusse, 2004) , matrigel migration analyses were performed on these cultures. The results showed a direct correlation between HBxAg transactivation and migration (Figure 5d ), and an inverse correlation between E-cadherin expression and migration, suggesting that HBxAg promotes hepatocellular migration, at least in part, by suppression of E-cadherin.
Relationship between E-cadherin expression and b-catenin translocation/activation in HCC Decreased expression of E-cadherin may contribute to the activation of b-catenin, the latter of which accumulates in the cytoplasm and nucleus (Bae et al., 2002; Prange et al., 2003) . To test this, tumor and nontumor tissues from South African and Chinese patients, and uninfected liver, were stained for b-catenin. b-catenin staining was membrane associated in uninfected liver (Figure 6a ), as expected. Normal IgG did not stain b-catenin in infected liver (Figure 6b) . However, strong, predominantly membranous staining, was observed in infected nontumor liver (Figure 6c ), while cytoplasmic/ nuclear staining was prevalent in HCC (Figure 6d) Hence, decreased E-cadherin expression was associated with the accumulation of b-catenin in the cytoplasm and nuclei of tumor cells. Since this is sometimes associated with mutations in the GSK3b-binding site of b-catenin, located in exon 3 of the b catenin gene this region was directly sequenced from 46 randomly chosen fresh frozen HCC blocks from as many patients. Exon 3 mutations were detected only in two cases. In one patient there was a TCT-GCT mutation at codon 37, which resulted in a change from serine to alanine. The other patient had a GCT-GAT mutation in codon 43, converting an alanine to aspartic acid. Hence, the accumulation of b-catenin in the cytoplasm and nuclei of tumor cells do not appear to be associated with exon 3 mutations (w 2 ¼ 0.375; P>0.5), but instead with decreased or absent expression of E-cadherin in tumors. To test whether HBxAg suppression of E-cadherin is associated with increased b-catenin activity, Hep3B cells expressing wild-type or mutant HBxAg were tested for b-catenin activity in a pTOPFLASH assay. When pTOPFLASH was transfected into cells making fulllength HBxAg (1-245) or truncated HBxAg (1-135) that are associated with decreased E-cadherin expression ( Figure 5 ), there was a corresponding increase in bcatenin activity, while HBxAg mutants or empty vector containing cells that were not associated with suppressed E-cadherin expression (Figure 5 ), did not stimulate b-catenin activity (Figure 6e ). Transient transfection of the mutant b-catenin-responsive element, pFOP-FLASH, was not active in this assay. Hence, HBxAg mediated decreased expression of E-cadherin is associated with the activation of b-catenin.
Discussion
E-cadherin is a cell surface protein that promotes cellcell adhesion and partially controls cell migration (Nelson and Nusse, 2004) . Downregulated expression of E-cadherin is common in HCC, with promoter methylation observed early in hepatocarcinogenesis, while LOH of the E-cadherin locus is common during tumor progression (Kanai et al., 1997 (Kanai et al., , 2000 . The findings that downregulation of E-cadherin is associated with chronic HBV infection (Wei et al., 2002) , that HBxAg promotes cell migration (Lara-Pezzi et al., 2001a, b) and reduces cell adhesion (Lian et al., 2003) , suggest that HBxAg may downregulate E-cadherin. The inverse correlation between HBxAg and E-cadherin in tissue culture cells (Figure 2 ) and in tumor/nontumor tissues (Figure 3) , and that HBxAg promotes E-cadherin promoter methylation (Figure 4) , support the hypothesis that HBxAg targets E-cadherin. Hence, the suppression of E-cadherin is likely to be another step whereby HBxAg contributes to multistep hepatocarcinogenesis.
There are several mechanisms whereby HBxAg may suppress E-cadherin. HBxAg may transcriptionally suppress E-cadherin, since the levels of E-cadherin mRNA is lower in HBxAg-positive cells compared to HBxAg-negative cells (Figure 2 ). HBxAg may alter the half-life of E-cadherin mRNA. However, the correlation between HBxAg trans-activation activity and the levels of endogenous E-cadherin mRNA in HepG2 cells ( Figure 5 ) suggests transcriptional repression. The latter may also occur if HBxAg trans-activates the E-cadherin transcriptional repressors, Snail and/or Slug (Jiao et al., 2002; Nelson and Nusse, 2004) .
A consequence of suppressed E-cadherin expression is activated Wnt signaling. Previous work has shown that Wnt signaling is activated in HBxAg-positive cells compared to HBxAg-negative cells by Wnt-1 (Cha et al., 2004) . The inverse correlation between E-cadherin expression and b-catenin cytoplasmic/nuclear translocation in HBxAg-positive cells and HCC/liver tissue (Figures 3 and 6) suggests that decreased E-cadherin is associated with activated b-catenin signaling (Orsulic et al., 1999) . The finding that activated b-catenin is associated with suppressed E-cadherin (Figure 6 ), suggests one mechanism whereby Wnt signaling is activated in HBxAg-positive cells during chronic infection. Alternatively, or in addition, the finding that activated bcatenin turns on the expression of genes that upregulate the expression of Slug, may provide another pathway whereby E-cadherin is suppressed in HBxAg-positive cells (Nelson and Nusse, 2004) . The finding that HBxAg stimulates src signaling, which disrupts E-cadherin/ b-catenin complexes (Lara-Pezzi et al., 2001c) , is yet another way that HBxAg may disrupt E-cadherin function. Whatever the mechanism(s), it is clear that HBxAg mutants that fail to suppress E-cadherin, stimulate b-catenin (Figure 6 ), but fail to stimulate the mobility of HepG2 cells ( Figure 5 ). This suggests a link between HBxAg function, E-cadherin/b-catenin expression, and the control of cell adhesion, the latter of which is lost in tumor development.
A potentially novel function of HBxAg is that it may alter DNA methylation (Figure 4) . While the mechanisms involved remain to be identified, this observation may explain the finding of E-cadherin promoter methylation in HBV-infected livers (Kanai et al., 1997 (Kanai et al., , 2000 Yang et al., 2003) . If HBxAg alters promoter methylation of many cellular genes, it would provide an explanation for some of the pleiotrophic properties of HBxAg. This may provide a common denominator for how HBxAg alters patterns of host gene expression, alters DNA conformation (by methylation), and alters chromosome stability (promoting LOH and chromosomal breakage) (Feitelson et al., 2002) . If so, then the suppressed expression of E-cadherin would provide one example of how HBxAg promotes the development of epigenetic changes that ultimately give rise to tumors.
Materials and methods
Cell culture
HepG2 cells were transduced with a recombinant retrovirus encoding HBxAg or the bacterial chloramphenicol acetyltransferase (CAT) gene. The resulting cultures, designated HepG2X and HepG2CAT, respectively, were selected for 2 weeks in G418 to eliminate cells that were not retrovirus infected. Cultures were then passaged and analysed without selection of individual clones. HBxAg and CAT expression were verified as described . HepG2 cells expressing individual HBxAg mutants were made and characterized as described . Likewise, HBxAg and HBxAg mutants were stably introduced into Hep3B cells. AML-12 cells, a nontransformed hepatocyte cell line isolated from transforming growth factor alpha transgenic mice (Wu et al., 1994) , and stably transfected with HBx under control of the tetracycline-inducible promoter, were cultured as HepG2 cells in the absence or presence of doxycycline (0.3 mg/ml for 72 h).
RNA isolation and microarray analysis
A total of 50 mg of total RNA from confluent HepG2X and HepG2CAT cells was isolated using the RNeasy kit (Qiagen, Valencia, CA, USA). These RNAs were sent to MERGEN, Ltd (San Leandro, CA, USA), where microarray analysis was performed using the human HO5 ExpressChip Array, which consists of prespotted oligonucleotide sequences from 12 800 cDNAs. These RNAs were subjected to analysis in three independent experiments. Array data were analysed using GeneSpringt and sent back to the lab as Excel tables on CD.
Powerblot analysis
Cell lysates were freshly prepared and shipped according to instructions provided by the contracting company (BD Transduction Labs, BD Biosciences, Medford, MA, USA) for PowerBlot analysis. Briefly, 400 mg of cell lysate from HepG2X or HepG2CAT cells were loaded across the top of 5-15% gradient SDS gels, and the mixtures separated by SDS/ PAGE. Proteins were transferred to immobilon P (Millipore, Bedford, MA, USA), the membranes were blocked with 5% milk, separated into vertical strips, and each strip blotted with a mixture of monoclonal antibodies to known proteins. Peroxidase-conjugated goat-anti-mouse Ig was used as secondary antibody, and the signals developed by chemiluminesence. For each of three experiments, three gels were prepared from lysates of HepG2X cells, and another three gels from lysates of HepG2CAT cells. In the entire analysis, Western blotting was performed for 792 proteins, although on any one gel, a small subset of antibodies was used for blotting in each lane. Images were captured electronically and were matched using PDQuest software (BioRad, Hercules, CA, USA). The results were returned to the lab as images and Excel tables on CD.
Reverse transcription-polymerase chain reaction (RT-PCR) Aliquots of total RNA (1 mg) were treated with DNase1 (Ambion, Austin, TX, USA) and used for cDNA synthesis using Two-Step RT-PCR Kits (Roche, Indianapolis, IN, USA). For E-cadherin mRNA amplification, the sense primer was 5 0 -TGCCCAGAAAATGAAAAAGG-3 0 and the antisense primer was 5 0 -GGATGACACAGGCGTGAGAGA-3 0 . For GAPDH, the sense primer was 5 0 -ACCACAGTCC ATGCCATCAC-3 0 while the antisense primer was 5 0 -TCCAC CACCCTGTTGCTGTA-3 0 . PCR was performed using Platinum Taq DNA Polymerase (Invitrogen, San Diego, CA, USA) at 951C for 1 min; 571C for 30 s, 721C for 1 min, 30 cycles; and then finally 721C for 2 min. Amplification without prior reverse transcription was used as a negative control. PCR products were visualized by ethidium bromide staining on 2% agarose gels.
Western blot analysis
Western blotting was carried out as described . Rabbit monoclonal anti-E-cadherin (1:400, sc-7870, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used as primary antibody. Horseradish peroxidase-conjugated goat anti-rabbit IgG (diluted 1:4000, Accurate Chemical Co., Westbury, NY, USA) was used as secondary antibody. Binding was detected utilizing enhanced chemiluminescence (Amersham, Upsalla, Sweden). Mouse antimonoclonal b-actin (Sigma Chemical Co., St Louis, MO, USA) used at 1:8000 dilution) was used as an internal control.
Immunostaining on HCC tissues and cell lines For HepG2X and HepG2CAT cells, equal numbers were grown on chamber slides for 72 h, acetone fixed, and then stained with anti-E-cadherin (1:300; sc-7870; Santa Cruz Biotech). For HCC and liver tissues, sections were deparaffinized and then rehydrated. Antigen retrieval, which enhances the sensitivity of staining through limited protease digestion of tissue sections, was performed using DAKO Antigen Retrieval Solution at 951C for 20 min according to product instructions. Sections were then cooled for 20 min at room temperature and rinsed with PBS three times. Staining was conducted as described (Wang et al., 1991) . Primary antibodies for Ecadherin (1:600; sc-7870; Santa Cruz Biotech), b-catenin (1:50; sc-7963; Santa Cruz Biotech), or HBxAg (Liu and Feitelson, 2004) in Antibody Diluent (DAKO) were incubated at 41C overnight. After washing 3 Â with Tris-buffered saline (pH 7.5), the DAKO EnVision þ System (DAKO, Carpinteria, CA, USA; Peroxidase Labelled Polymer Kit, Rabbit or Mouse) was used, followed by the Liquid DAB þ Substrate-chromogen solution. Slides were counterstained with Hematoxylin (Sigma). Normal mouse or rabbit IgG (Vector Labs) were used as negative controls in the place of primary antibodies. Precincubation of the primary antibody with the corresponding antigen was also used as a specificity control, as described (Liu and Feitelson, 2004) .
Staining was semiquantitatively evaluated by two observers who assigned a score for the intensity of staining and for the proportion of cells stained. The sum of these two values was used to calculate the TS (Vandeputte et al., 2002) . The intensity of the staining was stratified into four categories: 0, no immunoreactivity (IR); 1, weak ( þ ) IR; 2, moderate ( þ þ ) IR; and 3, strong ( þ þ þ ) IR. The proportion of positive cells was classified into four groups: 0, no tumor cells exhibiting IR; 0.33, o33% of the tumor cells exhibiting IR; 0.67, 33-67% of the tumor cells exhibiting IR; and 1, >67-100% of the tumor cells exhibiting IR.
Patient populations
Human HCC tumors (196 cases) and their corresponding nontumor liver tissues were obtained from South Africa (n ¼ 12) and China (n ¼ 184). South African samples were from patients in Johannesburg, while in China, samples were collected from the Second and Fourth Military Medical Universities in Shanghai and Xi'an, respectively. None of these samples were from patients who received other treatments prior to surgery. Formalin-fixed, paraffin-embedded tissues, fresh frozen blocks, and À801C snap frozen paired liver and tumor samples were collected from all patients, used for diagnostic purposes, and were then made available for these studies. Diagnosis of all tumor and nontumor tissue specimens were confirmed by pathological examination. Informed consent for tissue collection was obtained from all patients prior to operation. Uninfected human liver from two individuals were available as controls. This work was approved by the Institutional Review Board at Thomas Jefferson University.
The characteristics of the South African patients have been published . Among the Chinese, 196 total patients included 137 males and 59 females, aged between 14 to 72 years (mean age 52 years). There were 25 with grade I, 110 with grade II, 34 with grade III, and 27 with grade IV HCC. Liver cirrhosis was found in 168 (86%) of those with HCC. HBV infection was found in 156 patients (80%) infection. The latter group was positive for HBsAg or anti-HBs by standard serological assays (Auszyme or Ausab, respectively, Abbott Labs, North Chicago, IL, USA).
Bisulfite modification and methylation-specific PCR analysis Methylation-specific PCR was used to assess the methylation status of the E-cadherin promoter in HCC and adjacent liver in 20 HBxAg-positive and 20 HBxAg-negative cases (Herman et al., 1996) . A total of 50 ng of bisulfite-modified DNA was PCR amplified in a Roche 9600 thermocycler (Roche Molecular Systems, Pleasanton, CA, USA) using Platinum Taq DNA Polymerase (Invitrogen). Methylated DNA was detected using 5 0 -GGTGAATTTTTAGTTAATTAGCGGTA C-3 0 (sense) and 5 0 -CATAACTAACCGAAAACGCCG-3 0 . Amplification was conducted at 951C for 1 min; 951C for 20 s, 681C for 90 s, 35 cycles; and finally 681C for 2 min. Unmethylated DNA was detected using 5 0 -GGTAGGTGAA TTTTTAGTTAATTAGTGGTA-3 0 (sense) and 5 0 -ACCCA TAACTAACCAAAAACACCA-3 0 . Unmethylated DNA was amplified at 951C for 1 min; 951C for 20 s, 571C for 30 s, 721C for 1 min, 35 cycles; and finally 721C for 2 min. The PCR products were analysed by agarose gel electrophoresis. In all, 1 mg of genomic DNA from a normal (uninfected) human liver treated with 10 U of SssI methylase (New England Biolabs, Beverly, MA, USA) was used as a positive control for methylated DNA. The same amount of genomic DNA from a human normal liver without methylase treatment was used as negative control.
Detection of exon 3 mutations in b-catenin Exon 3 of the b-catenin gene was PCR amplified and sequenced at the DNA sequencing facility at the Kimmel Cancer Institute of Thomas Jefferson University. Exon 3 primers were 5 0 -ATTTGATGGAGTTGGACATGG-3 0 (forward) and 5 0 -TGTTCTTGAGTGAAGGACTGA-3 0 . For nested PCR, the primer 5 0 -TCTTCCTCAGGATTGCCTT-3 0 (forward) was used. PCR was performed with the Advantage 2 Polymerase Mix (BD Biosciences Clontech). The conditions for PCR amplification were: 951C for 1 min, 951C for 20 s, 681C for 1 min 30 s, 30 cycles; 681C for 2 min. PCR products were purified by the MiniElute PCR purification kit (Qiagen) prior to sequencing.
Migration assay
The cell migration assay was conducted using the BD BioCoatt Matrigelt Invasion Chamber according to enclosed instructions (BD Biosciences). For this work, 2.5 Â 10 5 cells were seeded into each well of six-well plates.
Northern blotting and HBxAg trans-activation assays These procedures were carried out exactly as described .
b-catenin activity assay
To measure b-catenin-signaling activity, cells were transiently transfected with the TCF reporter plasmids pTOPFLASH (which is b-catenin responsive) or pFOPFLASH (a mutant which is b-catenin unresponsive) (Upstate Technology, Charlottesville, VA, USA), and luciferase activity determined after 48 h.
Statistical analysis
Statistical analysis and graphic presentation were performed using the SPSS 10.0 for windows (SPSS Inc., Chicago, IL, USA) program package. The w 2 test was used for testing relationships between categorical variables as appropriate. Spearman's rank correlation coefficient analysis was used to assess the correlation between ordinal variables. Po0.05 denoted the presence of a statistically significant difference. The Student's t-test was used to assess differences between migration of HepG2X, HepG2X mutant and control cells.
